Source:http://linkedlifedata.com/resource/pubmed/id/12649124
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
12
|
| pubmed:dateCreated |
2003-6-10
|
| pubmed:abstractText |
Antagonizing the effect of interleukin (IL)-5 is a potential new treatment strategy in allergic disorders. We evaluated the safety, biological activity, and pharmacokinetics of SCH55700, a humanized anti-human IL-5 antibody, in subjects with severe persistent asthma treated with oral or high doses of inhaled steroids. In a double-blind, randomized, multicenter trial, a rising single dose of SCH55700 (0.03 mg/kg [n = 2], 0.1 mg/kg [n = 4], 0.3 mg/kg [n = 6], or 1.0 mg/kg [n = 12]) or placebo (n = 8) was administered intravenously. SCH55700 dose dependently reduced circulating eosinophil counts. At a dose of 1.0 mg/kg, the decrease remained significant up to Day 30 [(0.07 +/- 0.01) x 10(9)/L versus (0.23 +/- 0.04) x 10(9)/L at baseline] (mean +/- SEM) (p = 0.05). After administration of SCH55700 at 0.3 and 1.0 mg/kg, a trend toward improvement in baseline FEV1 was observed, which reached significance 24 hours after the 0.3-mg/kg dose (p = 0.019 versus placebo). No significant changes occurred in other clinical indices of disease activity. Adverse events were not different between active treatment and placebo. We conclude that SCH55700 is a biologically active anti-human IL-5 antibody that can be safely used in severe steroid-treated asthma. Its therapeutic potential needs to be addressed in specifically designed efficacy trials.
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
1073-449X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
15
|
| pubmed:volume |
167
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1655-9
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:12649124-Adult,
pubmed-meshheading:12649124-Analysis of Variance,
pubmed-meshheading:12649124-Anti-Asthmatic Agents,
pubmed-meshheading:12649124-Antibodies, Monoclonal,
pubmed-meshheading:12649124-Asthma,
pubmed-meshheading:12649124-Double-Blind Method,
pubmed-meshheading:12649124-Drug Monitoring,
pubmed-meshheading:12649124-Eosinophilia,
pubmed-meshheading:12649124-Eosinophils,
pubmed-meshheading:12649124-Female,
pubmed-meshheading:12649124-Forced Expiratory Volume,
pubmed-meshheading:12649124-Humans,
pubmed-meshheading:12649124-Immunoglobulin G,
pubmed-meshheading:12649124-Infusions, Intravenous,
pubmed-meshheading:12649124-Injections, Intravenous,
pubmed-meshheading:12649124-Interleukin-5,
pubmed-meshheading:12649124-Leukocyte Count,
pubmed-meshheading:12649124-Male,
pubmed-meshheading:12649124-Pilot Projects,
pubmed-meshheading:12649124-Safety,
pubmed-meshheading:12649124-Severity of Illness Index,
pubmed-meshheading:12649124-Treatment Outcome
|
| pubmed:year |
2003
|
| pubmed:articleTitle |
Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study.
|
| pubmed:affiliation |
Department of Respiratory Diseases, Ghent University Hospital, De Pintelaan 185, B 9000 Ghent, Belgium. johan.kips@rug.ac.be
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Multicenter Study
|